A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Clinical trial NCT07034508 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07034508
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-20
- Primary completion
- 2027-12-20
- Enrollment
- 134
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.